Psychotropic Drugs

NORMAN L. KELTNER, Ed D, RN
Associate Professor, Graduate Program,
University of Alabama School of Nursing,
University of Alabama at Birmingham,
Birmingham, Alabama

DAVID G. FOLKS, MD
Professor of Psychiatry and Behavioral Neurobiology,
University of Alabama School of Medicine,
University of Alabama at Birmingham,
Birmingham, Alabama

Illustrated

Mosby
St. Louis Baltimore Boston Chicago London Philadelphia Sydney Toronto
Contents

PART ONE CLINICAL PSYCHOPHARMACOLOGY, 1

UNIT I Introduction to Psychotropic Drug Use, 3

1 Psychiatric Care and Contemporary Treatment, 4
   Benchmarks in Psychiatric Care, 4
      Period of Enlightenment, 5
      Period of Scientific Study, 5
      Period of Psychotropic Drugs, 6
      Period of Community Mental Health Care, 6
   Remarks, 7

2 Review of Functional Neuroanatomy, 8
   Richard A. Sugerman
   Cleveland F. Kinney
   Supraspinal Motor Pathways, 18
   Limbic Lobe, 23

3 Review of Neurotransmitters, 26
   Richard A. Sugerman
   Synaptic Transmission, 26
      Types of Synapses, 27
   Membrane Receptors, 28
      Mechanisms of Receptor Action, 28
   Neurotransmission, 28
      Neuron Excitation and Inhibition, 28
      Defining Neurotransmitters, 29
   Action and Synthesis of Neurotransmitters, 29
      Cholinergic System, 29
      Monoamine Systems, 32
      Neuropeptides, 33
      Amino Acid Transmitters, 34
   Neurotransmitters and Neurochemistry of Behavior, 36

UNIT II Drugs Used in the Treatment of Mental Disorders, 41

4 Schizophrenia and Other Psychoses, 42
   Historical Considerations, 42
   DSM-III-R Terminology and Criteria, 44
   Antipsychotic Drugs, 45
      History, 45
      Classification Systems, 48
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixed Anxiety-Depression, 113</td>
<td></td>
</tr>
<tr>
<td>Generalized Anxiety, 113</td>
<td></td>
</tr>
<tr>
<td>Nonpsychiatric Anxiety, 115</td>
<td></td>
</tr>
<tr>
<td>Treatment, 115</td>
<td></td>
</tr>
<tr>
<td>Anxiolytics, 118</td>
<td></td>
</tr>
<tr>
<td>Benzodiazepines, 118</td>
<td></td>
</tr>
<tr>
<td>Pharmacologic Effect, 118</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics, 119</td>
<td></td>
</tr>
<tr>
<td>Side Effects, 122</td>
<td></td>
</tr>
<tr>
<td>Implications, 122</td>
<td></td>
</tr>
<tr>
<td>Buspirone, 125</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics, 126</td>
<td></td>
</tr>
<tr>
<td>Implications, 126</td>
<td></td>
</tr>
<tr>
<td>Specific Anxiety Disorders and Mixed Syndromes, 127</td>
<td></td>
</tr>
<tr>
<td>Panic Disorder, 128</td>
<td></td>
</tr>
<tr>
<td>Treatment, 129</td>
<td></td>
</tr>
<tr>
<td>Phobic Disorders, 131</td>
<td></td>
</tr>
<tr>
<td>Treatment, 131</td>
<td></td>
</tr>
<tr>
<td>Obsessive-Compulsive Disorder, 133</td>
<td></td>
</tr>
<tr>
<td>Treatment, 133</td>
<td></td>
</tr>
<tr>
<td>Posttraumatic Stress Disorder, 135</td>
<td></td>
</tr>
<tr>
<td>Treatment, 135</td>
<td></td>
</tr>
<tr>
<td>Mixed Anxiety-Depression, 136</td>
<td></td>
</tr>
<tr>
<td>Treatment, 136</td>
<td></td>
</tr>
<tr>
<td>7 Seizure Disorders, 139</td>
<td></td>
</tr>
<tr>
<td>Epilepsy, 139</td>
<td></td>
</tr>
<tr>
<td>Categories of Seizures, 139</td>
<td></td>
</tr>
<tr>
<td>Antiepileptic Drugs, 141</td>
<td></td>
</tr>
<tr>
<td>Hydantoins: Prototype Drug, Phenytoin, 143</td>
<td></td>
</tr>
<tr>
<td>Pharmacologic Effects, 144</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics, 144</td>
<td></td>
</tr>
<tr>
<td>Side Effects, 150</td>
<td></td>
</tr>
<tr>
<td>Implications, 150</td>
<td></td>
</tr>
<tr>
<td>Related Hydantoins, 154</td>
<td></td>
</tr>
<tr>
<td>Long-Acting Barbiturates: Prototype Drug, Phenobarbital, 154</td>
<td></td>
</tr>
<tr>
<td>Pharmacologic Effects, 154</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics, 155</td>
<td></td>
</tr>
<tr>
<td>Side Effects, 155</td>
<td></td>
</tr>
<tr>
<td>Implications, 156</td>
<td></td>
</tr>
<tr>
<td>Related Barbiturates, 157</td>
<td></td>
</tr>
<tr>
<td>Succinimides: Prototype Drug, Ethosuximide, 158</td>
<td></td>
</tr>
<tr>
<td>Pharmacologic Effects, 158</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics, 158</td>
<td></td>
</tr>
<tr>
<td>Side Effects, 159</td>
<td></td>
</tr>
<tr>
<td>Implications, 159</td>
<td></td>
</tr>
<tr>
<td>Related Succinimides, 160</td>
<td></td>
</tr>
<tr>
<td>Oxazolidinediones: Prototype Drug, Trimethadione, 160</td>
<td></td>
</tr>
<tr>
<td>Pharmacologic Effects, 160</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics, 160</td>
<td></td>
</tr>
<tr>
<td>Side Effects, 161</td>
<td></td>
</tr>
<tr>
<td>Implications, 161</td>
<td></td>
</tr>
</tbody>
</table>
Drug Treatment, 204
  Short-Term Treatment, 204
  Long-Term Treatment, 210
Implications and Treatment Issues, 212

10 Alcoholism and Other Substance Abuse Disorders, 215
  Scope of the Problem, 215
  Epidemiology, 215
    Historical Perspective, 215
    National Surveys, 216
    Pregnancy Considerations, 216
    Psychologic Considerations, 217
  Genetic, Environmental, and Other Influences, 217
    Genetic Influences, 217
    Environmental Influences, 217
    Psychiatric Influences, 218
    Drug-Related Influences, 218
    Endogenous Opiate Receptors, 219
  Diagnostic Considerations, 219
    American Psychiatric Association Considerations, 220
    Defining Key Factors, 220
    Comorbidity, 222
  Drug Treatment, 222
    Short-Term Treatment Objectives, 223
    Long-Term Treatment Objectives, 223
    Drugs Used in the Treatment of Alcoholism, 223
    Drugs Used to Treat Narcotic (Opioid) Dependence and Abuse, 225
    Drugs Used to Treat Effects of Central Nervous System Stimulants, 227
    Drugs Used to Treat Tobacco Dependence, 231
    Drugs Used to Treat Cannabis (Marijuana) Dependence, 233
    Drugs Used to Treat Abuse of Phencyclidine and Similar Agents, 234
    Drugs Used to Treat Sedative-Hypnotic and Anxiolytic Abuse and Dependence, 234

UNIT III Drug Issues Related to Psychopharmacology, 241

11 Drugs Used for Electroconvulsive Therapy, 242
  Historical Considerations, 242
    Historical Perspective on the Negative View, 243
  Modern Electroconvulsive Therapy, 243
    Indications, 243
    Contraindications, 246
    Advantages, 246
    Disadvantages, 246
  How Electroconvulsive Therapy Works, 247
  Drugs Used in Electroconvulsive Therapy, 247
    Succinylcholine, 247
    Pharmacokinetics and Interactions, 248
    Methohexital, 248
    Pharmacokinetics, 248
    Side Effects, 248
    Interactions, 249
Atropine, 249
  Pharmacokinetics, 249
  Side Effects, 249
  Interactions, 249

12 Drugs of Abuse, 251

Alcohol, 257
  Etiologic Theories, 257
  Pharmacokinetics, 258
  Physiologic Effects, 260
  Related Issues, 261

Other Central Nervous System Depressants, 264
  Barbiturates, 264
    Pharmacokinetics, 265
    Physiologic Effects, 265
    Related Issues, 265
  Inhalants, 266

Narcotics (Opioids), 266
  Pharmacokinetics, 266
  Physiologic Effects, 266
  Related Issues, 267
  Specific Drugs, 268

Stimulants, 269
  Cocaine, 269
    Pharmacokinetics, 269
    Physiologic Effects, 270
  Amphetamines, 270
    Pharmacokinetics, 271
    Physiologic Effects, 271
    Related Issues, 271

Hallucinogens, 272
  Mescaline and Related Synthetic Substances, 272
    Pharmacokinetics, 272
    Physiologic Effects, 272
  Psilocybin, Psilocin, 273
    Pharmacokinetics, 273
    Physiologic Effects, 273
  Marijuana, 273
    Pharmacokinetics, 273
    Physiologic Effects, 273
  Lysergic Acid Diethylamide, 274
    Pharmacokinetics, 274
    Physiologic Effects, 274
  Phencyclidine, 274
    Pharmacokinetics, 274
    Physiologic Effects, 274
    Related Issues, 275

Remarks, 275
  Screening Tests, 276
13 Drugs Used to Stimulate the Central Nervous System, 278

Cerebral Stimulants, 278
  Amphetamines, 278
    Pharmacologic Effect, 279
    Pharmacokinetics, 280
    Side Effects, 281
    Implications, 282

Other Prescription Central Nervous System Stimulants, 284
  Methylphenidate, 284
    Pharmacokinetics, 285
    Side Effects, 285
    Implications, 285
  Pemoline, 286

Other Stimulants: Caffeine and Amphetamine-Like Anorectics, 286
  Caffeine, 286
  Phenylpropanolamine, 287

Treatment Considerations, 290
  Treatment of Depression, 290
  Treatment of Depressed Medically Ill Patients, 290
  Use as a Challenge Test for Predicting a Response to Antidepressants, 291
  Use in Elderly Persons, 291
  Caffeine Augmentation of Electroconvulsive Therapy, 291
  Treatment of Schizophrenia, 291
  Miscellaneous Uses, 291

14 Drugs Used to Treat Extrapyramidal Side Effects, 293

Review of Parkinsonism, 293
  Drugs Used to Treat Parkinsonism, 296

Anticholinergic Antiparkinson Agents, 299
  Pharmacologic Effects, 299
  Pharmacokinetics, 299
  Side Effects, 299
  Implications, 300
  Patient Education, 301

Related Anticholinergic Antiparkinson Drugs, 302
  Benztropine, 302
  Biperiden, 302
  Procyclidine, 302
  Diphenhydramine, 303

Issues in Antiparkinson Drug Administration, 303

Other Agents, 305
  Benzodiazepines: Treatment of EPSEs, 305
  Beta-Adrenergic Antagonists: Treatment of EPSEs, 305
  Clonidine: Treatment of EPSEs, 305
  Nifedipine and Verapamil: Treatment of Tardive Dyskinesia, 305
  Dantrolene: Treatment of Neuroleptic Malignant Syndrome, 305